CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 93 filers reported holding CARDIFF ONCOLOGY INC in Q2 2021. The put-call ratio across all filers is 1.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,850 | -5.4% | 15,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $22,050 | -10.9% | 15,000 | 0.0% | 0.00% | -25.0% |
| Q1 2023 | $24,750 | +17.9% | 15,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $21,000 | -8.7% | 15,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $23,000 | -30.3% | 15,000 | 0.0% | 0.00% | -33.3% |
| Q2 2022 | $33,000 | -10.8% | 15,000 | 0.0% | 0.01% | -14.3% |
| Q1 2022 | $37,000 | -58.9% | 15,000 | 0.0% | 0.01% | -58.8% |
| Q4 2021 | $90,000 | -10.0% | 15,000 | 0.0% | 0.02% | -15.0% |
| Q3 2021 | $100,000 | -24.8% | 15,000 | -25.0% | 0.02% | -25.9% |
| Q2 2021 | $133,000 | -42.7% | 20,000 | -20.0% | 0.03% | -47.1% |
| Q1 2021 | $232,000 | -48.4% | 25,000 | 0.0% | 0.05% | -50.5% |
| Q4 2020 | $450,000 | +26.8% | 25,000 | 0.0% | 0.10% | +18.4% |
| Q3 2020 | $355,000 | +184.0% | 25,000 | 0.0% | 0.09% | +171.9% |
| Q2 2020 | $125,000 | – | 25,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 2,522,083 | $16,797,000 | 13.61% |
| Octagon Capital Advisors LP | 982,753 | $6,545,000 | 1.61% |
| Altium Capital Management LP | 348,888 | $2,324,000 | 0.61% |
| ACT CAPITAL MANAGEMENT, LLC | 102,500 | $683,000 | 0.35% |
| Eventide Asset Management | 1,670,399 | $11,125,000 | 0.15% |
| Artal Group S.A. | 750,000 | $4,995,000 | 0.11% |
| Virtus ETF Advisers LLC | 25,770 | $172,000 | 0.08% |
| HighVista Strategies LLC | 15,501 | $103,000 | 0.07% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 13,500 | $90,000 | 0.05% |
| SCHOLTZ & COMPANY, LLC | 16,625 | $111,000 | 0.04% |